Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31607448 | 1.00 | LMNA (0.43) | LMNA | |
| SCHEMBL932016 | 0.97 | — | — | |
| SCHEMBL669828 | 0.89 | — | — | |
| SCHEMBL10535505 | 0.80 | LMNA (0.59) | LMNA | |
| SCHEMBL10535502 | 0.80 | LMNA (0.59) | LMNA | |
| SCHEMBL8514671 | 0.78 | LMNA (0.48) | LMNA | |
| SCHEMBL336892 | 0.77 | — | — | |
| SCHEMBL31187923 | 0.77 | ACE2 (0.47) | LMNA | |
| SCHEMBL11723029 | 0.76 | LMNA (0.67) | LMNA | |
| SCHEMBL20530387 | 0.76 | LMNA (0.67) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2025-03-06 | — | — | US | disclosed |
| US-12077483-B2 | Modified amine lipids | INTELLIA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20220119341-A1 | MODIFIED AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3891127-A1 | MODIFIED AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-110982047-B | Indacarbazine difuranyl organic solar cell donor material, and preparation method and application thereof | 河南大学 | 2020-11-24 | — | — | CN | disclosed |
| WO-2020118041-A1 | MODIFIED AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| CN-110982047-A | Indacarbazine difuranyl organic solar cell donor material, and preparation method and application thereof | 河南大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-101646643-B | Method for producing cross-coupled compound | KAO CORP | 2013-06-05 | — | — | CN | disclosed |
| US-8283482-B2 | Method for producing cross-coupling compound | KAO CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20100048929-A1 | METHOD FOR PRODUCING CROSS-COUPLING COMPOUND | KAO CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| CN-101646643-A | Method for producing cross-coupled compound | KAO CORP JP | 2010-02-10 | — | — | CN | disclosed |
| EP-2143705-A1 | METHOD FOR PRODUCING CROSS-COUPLING COMPOUND | Kao Corporation (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048929-A1 | METHOD FOR PRODUCING CROSS-COUPLING COMPOUND | FASN, ELOVL3, ELOVL1 | LMNA 437/4885 |
| US-12077483-B2 | Modified amine lipids | PHOSPHO1, SGMS1, SGMS2 | LMNA 1381/4885 |
| US-20220119341-A1 | MODIFIED AMINE LIPIDS | PHOSPHO1, SGMS1, SGMS2 | LMNA 1381/4885 |
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | PHOSPHO1, SGMS1, SGMS2 | LMNA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.